- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02098343
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium, 2650
- Antwerp University Hospital
-
Brussels, Belgium, 1000
- Institut Jules Bordet
-
Brussels, Belgium, B-1200
- Cliniques Universitaires Saint Luc
-
Gent, Belgium, 9000
- Medische oncologie, Universitair Ziekenhuis Gent
-
Leuven, Belgium, B-3000
- Leuven University Hospitals
-
-
-
-
-
Lyon, France, 69373
- Centre Leon Berard
-
Lyon, France, 69495
- Centre Hospitalier Lyon Sud
-
Nantes, France, 44202
- Centre Catherine De Sienne
-
Paris, France, 75005
- Institut Curie
-
Paris, France, 75012
- Hôpital des Diaconesses (Site Reuilly)
-
Strasbourg, France, 67065
- Centre Paul Strass
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
-
-
-
Berlin, Germany, 13353
- Charité Campus Virchow-Klinikum
-
Berlin, Germany, 10367
- Praxisklinik, Krebsheilkunde für Frauen
-
Dresden, Germany, 01307
- Universitatsklinikum Carl Gustav Carus
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
Ulm, Germany, 89075
- Universitätsfrauenklinik Ulm
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Academisch Medisch Centrum
-
Groningen, Netherlands, 9700 RB
- Universitair Medisch Centrum Groningen
-
Leiden, Netherlands, 2300 RC
- Leids Universitair Medisch Centrum
-
Maastricht, Netherlands, 6229 HX
- Academisch Ziekenhuis Maastricht
-
-
-
-
-
Badalona, Spain, 08916
- Institut Català d'Oncologia, Hospital Germans Trias i Pujol
-
Barcelona, Spain, 08035
- Hospital Vall d'Hebron
-
Córdoba, Spain, 14004
- Hospital Universitario Reina Sofia
-
Madrid, Spain, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Madrid, Spain, 28050
- Hospital Universitario HM Sanchinarro
-
Madrid, Spain, 28033
- Centro Oncológico MD Anderson
-
Málaga, Spain, 29010
- Hospital Universitario Virgen de la Victoria
-
Valencia, Spain, 46010
- Hospital Clínico Universitario de Valencia
-
Vitoria-Gasteiz, Spain, 01009
- Hospital Universitario Araba
-
Zaragosa, Spain, 50009
- Hospital Clinico Universitario Lozano Blesa
-
-
-
-
-
Stockholm, Sweden, SE-171 76
- Karolinska University Hospital
-
-
-
-
-
Bristol, United Kingdom, BS2 8ED
- Bristol Haematology & Oncology Centre, University Hospitals Bristol
-
Cambridge, United Kingdom, CB2 0QQ
- Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
-
Edinburgh, United Kingdom, EH4 2XR
- Edinburgh Cancer Research Centre, The University of Edinburgh
-
Liverpool, United Kingdom, CH63 4JY
- The Clatterbridge Cancer Center NHS Foundation Trust
-
London, United Kingdom, SM2 5PT
- The Royal Marsden NHS Foundation Trust
-
London, United Kingdom, W12 0NN
- Imperial College London, Hammersmith Hospital Campus
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS foundation Trust
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Hillman Cancer Center, Magee-Womens Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75390
- Parkland, UT Southwestern Medical Center
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Massey Cancer Center, Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53
- Disease Progression between 6-24 months after a first or second platinum based regimen
- At least a single measurable lesion. Phase II patients only
- Adequate organ function prior to registration
- Toxicities from previous cancer therapies must have recovered to grade 1 (defined by Common Terminology Criteria for Adverse Events [CTCAE] 4.0) Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis
- ECOG performance status of 0 to 1
Exclusion Criteria:
- Prior exposure to cumulative doses of doxorubicin >400 mg/m2 or epirubicin >720 mg/m2
- History of allergic reactions to carboplatin, platinum containing compounds or mannitol and/or hypersensitivity to PLD or to any of the excipients
- Unable to undergo imaging by either CT scan or MRI
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications
- Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ)
- Is taking concurrent (or within 4 week prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.
Dose escalation of APR-246.
|
Intravenous infusion.
Intravenous infusion.
|
Experimental: Phase II: Arm A. APR-246 + Carboplatin/PLD.
Experimental
|
Intravenous infusion.
Intravenous infusion.
|
Active Comparator: Phase II: Arm B. Carboplatin/PLD.
Active Comparator
|
Intravenous infusion.
|
Experimental: Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.
Dose escalation of APR-246.
|
Intravenous infusion.
Intravenous infusion.
|
Experimental: Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.
Dose escalation of APR-246.
|
Intravenous infusion.
Intravenous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen
Time Frame: Until the end of the first treatment cycle, i.e., Day 28
|
DLT: Hematological and non-hematological toxicities according to grade/days stated in the protocol.
|
Until the end of the first treatment cycle, i.e., Day 28
|
Phase Ib and II: Progression Free Survival (PFS)
Time Frame: Up to 24 months
|
Phase Ib: Progression-free Survival is calculated from date of enrollment to the date of disease progression or death due to any cause, whichever occurs first. Symptomatic deterioration is not considered PD. For a patient without evidence of disease progression or death, Progression-free survival will be censored at the date of last evaluable tumor assessment. Patients with no evaluable tumor assessments will be censored at the date of first study drug administration. Phase II: Progression-free survival (PFS) based on Blinded Independent Central Review (BICR) is the primary endpoint and is defined as the number of days from the date of randomization to the date of objective disease progression or relapse (according to RECIST v1.1 only) or death due to any cause, whichever occurs first. If neither event occurs, PFS is censored at the date of the last evaluable tumor assessment. Symptomatic deterioration is not considered objective disease progression. |
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase Ib and Phase II: Overall Response Rate (RR)
Time Frame: Up to 24 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John A Green, Dr, Coordinating Investigator. Clatterbridge Centre for Oncology, UK
Publications and helpful links
General Publications
- Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.
- Deneberg S, Cherif H, Lazarevic V, Andersson PO, von Euler M, Juliusson G, Lehmann S. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60. No abstract available.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease Attributes
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Recurrence
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Carboplatin
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- APR-407
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...United States
-
National Cancer Institute (NCI)NRG OncologyWithdrawnRecurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)CompletedUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingOvarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian CarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
Clinical Trials on APR-246
-
Aprea TherapeuticsCompletedProstatic Neoplasms | Hematologic NeoplasmsSweden
-
Peter MacCallum Cancer Centre, AustraliaTerminated
-
Curatek Pharmaceuticals, LLCCompletedVaginal InfectionUnited States
-
Aprea TherapeuticsTerminatedMantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin LymphomaUnited States
-
Aprea TherapeuticsCompletedGastric Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Urothelial CarcinomaUnited States
-
Aprea TherapeuticsCompletedMDSUnited States, France
-
Mahidol UniversityUnknown
-
Aprea TherapeuticsCompletedMyeloid MalignancyUnited States
-
Aprea TherapeuticsCompletedAcute Myeloid Leukemia or Myelodysplastic SyndromesUnited States
-
Aprea TherapeuticsJules Bordet InstituteTerminated